


site. In these instances, the vaccine can be given in the anterolateral thigh (vastus lateralis muscle). 1,5-8 Active immunizing agents, including COVID-19 vaccines, should not be administered in the buttock (gluteal) muscle as an alternative site to the deltoid muscle. 1 Figure 1: Landmarking for Intramuscular Injections in the Deltoid Muscle



RR BUY ANABOLICS ONLINE RR

#### Nursing guidelines: Intramuscular Injections - The Royal Children's.



Intramuscular (IM) injections are shots delivered to a large muscle. They can be given by a healthcare provider or self-administered to the upper arm, thigh, buttock, or hip. IM injections are used for people of all ages, including infants.

# **ACIP Vaccine Administration Guidelines for Immunization | CDC**

|                        |                 |  | Not immunocompromised |                       | Moderate to severe immunocompromise |                                      |
|------------------------|-----------------|--|-----------------------|-----------------------|-------------------------------------|--------------------------------------|
| Age                    | Vaccine         | Туре   | Dose                  | Interval              | Dose                                | Interval                             |
| 6 months<br>to 5 years | Moderna         | Monovalent (blue cap,<br>magenta label border)   | 1 and 2               | At least 4 to 8 weeks | 1 and 2<br>2 and 3                  | At least 4 weeks                     |
|                        |                 | Bivalent (dark pink cap,<br>yellow label border) | 2 and 3               | At least 8 weeks      | 3 and 4                             | At least 8 weeks                     |
| 6 months<br>to 4 years | Pfizer-BioNTech | Monovalent (maroon cap,<br>maroon label border)  | 1 and 2               | At least 3 to 8 weeks | 1 and 2                             | At least 3 weeks                     |
|                        |                 | Bivalent (maroon cap,<br>maroon label border)    | 2 and 3               | At least 8 weeks      | 2 and 3                             | At least 8 week                      |
| 6 to 11<br>years       | Moderna         | Monovalent (blue cap,<br>purple label border)    | 1 and 2               | At least 4 to 8 weeks | 1 and 2<br>2 and 3                  | At least 4 weeks                     |
|                        |                 | Bivalent (blue cap, gray label border)           | 2 and 3               | At least 8 weeks      | 3 and 4                             | At least 8 weeks                     |
| 5 to 11<br>years       | Pfizer-BioNTech | Monovalent (orange cap, orange label border)     | 1 and 2               | At least 3 to 8 weeks | 1 and 2<br>2 and 3                  | At least 3 weeks                     |
|                        |                 | Bivalent (orange cap, orange label border)       | 2 and 3               | At least 8 weeks      | 3 and 4                             | At least 8 week:                     |
| 12 years<br>and older  | Moderna         | Monovalent (red cap, blue label border)          | 1 and 2               | At least 4 to 8 weeks | 1 and 2<br>2 and 3                  | At least 4 weeks                     |
|                        |                 | Bivalent (blue cap, gray label border)           | 2 and 3               | At least 8 weeks      | 3 and 4                             | At least 8 week                      |
|                        | Pfizer-BioNTech | Monovalent (gray cap, gray label border)         | 1 and 2               | At least 3 to 8 weeks | 1 and 2<br>2 and 3                  | At least 3 week:<br>At least 4 week: |
|                        |                 | Bivalent (gray cap, gray label border)           | 2 and 3               | At least 8 weeks      | 3 and 4                             | At least 8 weeks                     |
|                        | Novavax         | Monovalent                                       | 1 and 2               | At least 3 to 8 weeks | 1 and 2                             | At least 3 weeks                     |
|                        |                 | Bivalent (Moderna or<br>Pfizer-BioNTech)         | 2 and 3               | At least 8 weeks      | 3 and 4                             | At least 8 week                      |

The patient can be standing, sitting, or lying down. To locate the landmark for the deltoid muscle, expose the upper arm and find the acromion process by palpating the bony prominence. The injection site is in the middle of the deltoid muscle, about 1 inch to 2 inches (2. 5 cm to 5 cm) below the acromion process.

# Preparing and Administering Intramuscular Injections - JoVE



Aqueous solutions can be given with a 20- to 25-gauge needle; oily or viscous medications should be administered with 18- to 21-gauge needles. A smaller gauge needle (22 to 25 gauge) should be used with children. The deltoid muscle has a triangular shape and is easy to locate and access. To locate the injection site, begin by having the .

# Can 2 ml of fluid be administered in deltoid muscle?

| Table 1. Injectable volumes per site in adults   |                |  |  |  |
|--|----------------|--|--|--|
| Site   | Maximum volume |  |  |  |
| Ventrogluteal<br>(recommended)                   | 2.5ml          |  |  |  |
| Vastus lateralis<br>(recommended)                | 5ml            |  |  |  |
| Deltoid  | 1ml            |  |  |  |
| Rectus femoris                                   | 5ml            |  |  |  |
| Dorsogluteal<br>(not recommended)                | 4ml            |  |  |  |
| Source: Adapted from Dougherty and Lister (2015) |                |  |  |  |


Locations How to give an intramuscular injection Tips Complications Takeaway An intramuscular injection delivers medication into a muscle. Doctors frequently use intramuscular injections to.

# Inadequate deltoid muscle penetration and concerns of improper COVID.




Begin by having the patient relax the arm. The patient can be standing, sitting, or lying down. To locate the landmark for the deltoid muscle, expose the upper arm and find the acromion process by palpating the bony prominence. The injection site is in the middle of the deltoid muscle, about 2. 5 to 5 cm (1 to 2 inches) below the acromion process.

#### PDF Vaccine Administration: Intramuscular (IM) Injection Adults 19 years of .



In the case of IM injections, you should be particularly aware of the patient's preference for an injection site and administration process . are preferred for the administration of larger volumes of medications, while small volumes can be given to the arm, in the deltoid muscle. The deltoid site is mostly commonly used for immunizations .

# **Intramuscular Injections - Acute care | Elsevier - Clinical Skills**



Sep 17, 2010 I'm with them. I've always been told 1ml max in the detoid. healthstar, BSN, RN 1 Article; 944 Posts Sep 17, 2010 I was told 0. 5 ML max chansen

# Rules about intramuscular injection in children: - Armada Hospital JLT.




Locations of six examined sites in young adults. A: In the deltoid muscle, three finger breadths below the mid-acromion (MA) was defined as (a), and the point on the anteroposterior axillary line (b) was defined as that located at the intersection of the perpendicular line from MA and the horizontal line between the upper end of the anterior axillary line (AAL) and upper end of the posterior .

# How and where is a deltoid IM injection given? - Drugs



small dose (< 2 mL) injection length The deltoid is the preferred site when administering a volume of these sites? Assessing BMI to sel ct the app opriate site and needle


# 7. 4: Intramuscular Injections - Medicine LibreTexts



Pull or push the skin 2 to 3 cm away from the injection site with the nondominant hand

A deltoid IM injection is given into a specific area of the deltoid muscle located in your upper arm. Many vaccinations are given by this route. There are several different ways to find the deltoid muscle injection site, which is the central and thickest portion of the deltoid muscle, for example:

#### 18. 6 Administering Intramuscular Medications - Nursing Skills - 2e



Dispose of both the syringe and the medicine. Get more medicine in a new syringe. When you give the second injection, give it on the other side. Inject the medicine: Push down on the plunger to inject the medicine. Do not force the medicine by pushing hard. Some medicines hurt. You can inject the medicine slowly to reduce the pain.

## The Best Intramuscular (IM) Injection Sites - Verywell Health



The deltoid muscle is preferred for children aged 3-10 years; the needle length for deltoid site injections can range from  $\frac{5}{8}$  to 1 inch on the basis of technique. The anterolateral thigh can also be used . In this case the needle length should be 1 inch to 1. 25 inches.

#### Deltoid Intramuscular Injections: A Systematic Review of Underlying.


Open Access Review Article Cureus Deltoid Intramuscular Injections: A Systematic Review of Underlying Neurovascular Structures to the Muscle and Proposing a Relatively Safer Site node <sup>1</sup>, Shelja Sharma <sup>2</sup>, Sudhir Shyam Kushwaha <sup>3</sup>, Simmi Melua <sup>3</sup>, Sarah S. Sangma <sup>3</sup>, Vivek Anatomy, All India Institute of Medical Sciences, Rajkot, IND. 2. Anatomy, All India Institute of Medical Sciences, Gozábpur, IND. 3. Department of Orthopedics, All India Institute of Medical Sciences, Gozábpur, IND. Abstract The deboid is the preferred site for intransacular injection (IMI) because of its easy accessibility for drug and vaccine administration. Government immunization advisories, standard anatomy textbooks, and researchers have proposed various injection techniques and sites, but specific guidelines are lacking for the administration of tMIs in the increasingly used deltoid site. This study analyzes the procedures of administering tMIs in the deltoid related to the neurovascular network underlying the muscle and proposes a preferred site with the least chance of injury. The review protocol was submitted with PROSPERO (ID: 319251). PubMed, Google Scholar, and Websites of National Public Health Agencies were searched from 1950 up to 2022 for articles, advisories, and National Immunication Gaidelines using Medical Subject Headings (MoSH) terms, including IMIs, deltoid muscle, safe injection sites, to identify recommendations for safer sites and techniques of administering deltoid DMs. All the authors strictly adhered to a well-developed registered eview protocol throughout the study and followed the risk of bias in systematic reviews. (ROBIS) guidance tool. The proposed sites and landmark data were tabulated, and each site was analyzed. based on the underlying ne rovascular structures. Data were depicted by self-generated images The initial search identified 174 articles. After applying the inclusion and exclusion criteria, 57 articles were shortlisted. Out of the 39 selected articles, 18 focused on the administration of deltoid IMIs, whereas seven focused on the variations in the underlying neurovancular structures in proximity to the deltoid muscle. The remaining 14 articles were the immunization guides insued by the National Public Health Agencies of the Government of India and abroad, whose data was used for comparison. Twelve deltoid IMI siles and techniques were identified. A site 1-3 fingerbroadits, 5 cm below the mid-acromion point (7 studies); mid deltoid site-idensest part of the deltoid (1 study); a site at the middle third of the deltoid muscle (1 study); triangular injection site (1 study). Limitations included the unavailability of free access to complete test many articles resulting in exclusion. The area around the shoulder joint and up to the lower level of the intertubercular sulcus is highly vascularized by the presence of many anomalous arterial patterns. To avoid injury, a safer site is proposed of 5 fingerbreadths/10 cm below the esidpoint of the lateral border of the acronson. The authors received no specific funding for this study except for the journal publication charges Categories: Family General Practice, Epidemiology Public Health, Anatomy Keywords: needle depth, azillary nerve, sale site for injection, deboid muscle, intramuscular injection Introduction And Background Intramuncular injections (IMIs) are among the most common medical procedures performed in any healthcare center [1]. Globally, the deltoid is the preferred IMI site in clinical practice [1]. Many other IMI

Intramsucular injections (IMIs) are among the most common medical procedures performed in any healthcare center [1]. Isolabil, the deleted is the preferred IMI site in clinical practice [1]. Many other IMI sites have been considered over the deleted based on the risk of injury to the underlying vessels and nerves. However, a paucity of uniform guidelines and algorithms penistra for IMI administration by healthcare professionals [2]. This study analyzes the procedures of IMI administration in the delivad in relation to the arterial network underlying the muscle. Our study proposes a site preferred to the delivad for IMIs with the least chance of injury to neuroruscular structures. Figure / and Table / present the structures underlying the defined muscle.

How to cits this article
Chamode S, Danes S. Kushwaha S, et al. (April 15, 2022) Deltoid Intramuscular Injections: A Systematic Review of Underlying Neurovascular
Shrutners to the Nucle and Proposing a Relatively Safer Sis. Cureus 14(4): e34172. DOI 10.7756/cureus.24172

The deltoid is the preferred site for intramuscular injection (IMI) because of its easy accessibility for drug and vaccine administration. Government immunization advisories, standard anatomy textbooks, and researchers have proposed various injection techniques and sites, but specific guidelines are lacking for the administration of IMIs in the increasingly used deltoid site.

# 18. 6: Administering Intramuscular Medications - Medicine LibreTexts



IM injections are administered in five potential sites: deltoid (commonly used for adult vaccinations), dorsogluteal, ventrogluteal, rectus femoris, and vastus lateralis 3,10,11 (Figure 1).


# Large-volume IM injections: A review of best practices

TABLE. Overview of injection-site reactions in clinical studies of fulvestrant

| Study  | Phase                              | Treatments   | Incidence of ISRs   |
|--|------------------------------------|--|---|
| First-line the   | rapy                               |  |   |
| FIRST×   | 2                                  | Fulvestrant 500 mg/monthy vs anastrozole 1 mg/day  | Fulvestrant: 1.3% (14) of all administrations<br>(two 250-mg injections) and 5.9% (6) of patients                         |
| Study 25 <sup>th</sup>                                   | 3                                  | Fulvestrant 250 mg/month <sup>a</sup> vs tamoxifen 20 mg/day, orally   | Fulvestrant: 2.9% (9 of 310 patients) Tamostfen (placebo injection): 1.1% (3 of 271 patients)                             |
| Second-line t  | therapy                            |  |   |
| CONFIRM®   | 3                                  | Fulvestrant 250 mg/month* + placebo (5-ml. injections of each) vs fulvestrant 500 mg/month*  | 250 mg/month: 13.4% (50 of 374 patients)<br>500 mg/month: 13.6% (49 of 361 patients)                                      |
| FINDER 1 <sup>22</sup>                                   | 2                                  | Fulvestrant 250 mg/month <sup>a</sup> vs<br>Fulvestrant LD <sup>a</sup> vs<br>Fulvestrant 500 mg/month <sup>a</sup>  | 250 mg/month: 31.196* (14 of 45 patients)<br>LD: 21.696* (11 of 51 patients)<br>500 mg/month: 30.496* (14 of 46 patients) |
| FINDER 2 <sup>th</sup>                                   | 2                                  | Fulvestrant 250 ring/month? vs<br>Fulvestrant LD: vs<br>Fulvestrant 500 ring/month?  | 250 mg/month: 10 6/kf (5 of 47 patients)<br>LD: 10.0% (5 of 50 patients)<br>500 mg/month: 6.5% (3 of 46 patients)         |
| Trial 0020 <sup>pt</sup>                                 | 3                                  | Fulvestrant 250 mg/month+ (single 5-mL injection) vs<br>Anastrozole 1 mg/day   | Fulvestrant: 1.1% of courses  |
| Trial 0021 <sup>21</sup>                                 | 3                                  | Fulvestrant 250 mg/month* (two 2.5-ml. injections) + placebo vs<br>anastrozole 1 mg/day + placebo  | Fulvestrant: 4.6% of courses<br>Placebo: 4.4% of courses  |
| Fulwettant 250<br>Fulwettant LD: 5<br>Rejection site per | mg/month 25<br>100 mg on day<br>In | Ding on days 0, 14, and 28 of month 1; then every 28 days thereafter<br>Oing every 28 days<br>0, 250 mg on days 14 and 28 of month 1, then 250 mg every 28 days thereafter                         |   |
|  | t, Faskoder Inw                    | Fasiodias in Recument or Metarsatic Bruast Cancer, FIRIDER 1, Fasiodiae Investigation of<br>estigation of Dose Evaluation in Estrogen Receptor Positive Advanced Breast Cancer 2,<br>loading dose. |   |

Deltoid. The deltoid muscle is the preferred injection site in children aged 3-18 years when muscle mass is more developed. It is suitable for small volume injections. The recommended volume is 1ml; however, up to 2mls can be administered. The deltoid muscle is a rounded triangle shape.

## PDF How to Administer Intramuscular and Subcutaneous Vaccine Injections to .



Two ml dosages should go deep IM in the gluteal muscle. Not knowing what medication you are talking about, I would DEFINITELY double check the dosage that you are giving and the order, check it with the pharmacist if necessary.

## Anatomically safe sites for intramuscular injections: a cross-sectional.



Observing the large numbers of recently published media images of persons receiving their vaccine, the authors noted that in many cases the injection technique involved "bunching" of the skin over the injection site i. e. folding the skin overlaying the deltoid muscle between two fingers and inserting the hypodermic needle into the fold (Fig .

## Can 2 ml of fluid be administered in deltoid muscle?

| Table 1. Injectable volumes per site in adults   |                |  |  |  |
|--|----------------|--|--|--|
| Site   | Maximum volume |  |  |  |
| Ventrogluteal<br>(recommended)                   | 2.5ml          |  |  |  |
| Vastus lateralis<br>(recommended)                | 5ml            |  |  |  |
| Deltoid  | 1ml            |  |  |  |
| Rectus femoris                                   | 5ml            |  |  |  |
| Dorsogluteal<br>(not recommended)                | 4ml            |  |  |  |
| Source: Adapted from Dougherty and Lister (2015) |                |  |  |  |

Intramuscular route offer a faster rate of absorption than subcutaneous injection, it can hold a volume of fluid in children which is 0. 5-2ml depending on the child size. 2. In children age less than 2 years the recommended site of injection is the leg muscle vastus lateralis, middle part and the lateral aspect of the muscle; shown in the figure.

#### Optimal Intramuscular Injection Site and Maximum Volume in Adult Population

# **IM Injections: Other Ages**



#### Sites:

Deltoid:

Toddler (1-2 years) Child/adolescents (3-18 years)

Adults (19 years and older)

Anterolateral thigh:

Toddlers

Children/adolescents

Adults

#### **Needle Size:**

Toddlers 5/8"-1" deltoid \* Children /Adolescents 1 "-1 1/4" thigh

22-25 gauge

Adults 1"-1 1/2" deltoid/thigh\*

22-25gauge

\*Indicates alternate locations if deemed


necessary after assessment



We Protect Lives.


1. Use the correct syringe and needle. Administer vaccine using either a 1-mL or 3-mL syringe. Use a 22- to 25-gauge needle. Use the correct needle length based on the patient's gender and weight. For adults, use a 1- to 1. 5-inch needle. 1. 5 in (38 mm) OR 1 in (25 mm) in (25 mm) Men and women, less than 60 kg\* (130 lbs) Men and women,

## Intramuscular injection: Locations and administration - Medical News Today



Intramuscular (IM) injections have been associated with adverse effects and pain, and this route of medication injection should be used as a last resort. Consider contacting the practitioner for an alternative, preferred route of medication administration. Take steps to eliminate interruptions and distractions during medication preparation.

#### PDF Immunization Technique for Intramuscular (IM) Injections Deltoid Muscle



Use a needle long enough to reach deep into the muscle. Insert the needle at a 90° angle to the skin with a quick thrust. Separate two injections given in the same deltoid muscle (or anterolateral thigh muscle, if using) by a minimum of 1". acromion process. • (bony prominence above deltoid)

- https://collectednotes.com/aas2024reviwer/stanabol-50-alchemia
- <a href="https://publiclab.org/notes/print/41712">https://publiclab.org/notes/print/41712</a>
- https://publiclab.org/notes/print/43167